How are ALKS strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ALKS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 38.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$200.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ALKS strangle?

The breakeven for the ALKS strangle priced on this page is roughly $34.00 and $42.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALKS market-implied 1-standard-deviation expected move is approximately 11.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ALKS implied volatility affect this strangle?

ALKS ATM IV is at 38.80% with IV rank near 10.25%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

ALKS Strangle Strategy

ALKS (Alkermes plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS (Alkermes plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.49B, a trailing P/E of 42.34, a beta of 0.26 versus the broader market, a 52-week range of 25.17-39.56, average daily share volume of 2.4M, a public-listing history dating back to 1991, approximately 2K full-time employees. These structural characteristics shape how ALKS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.26 indicates ALKS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 42.34 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a strangle on ALKS?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ALKS snapshot

As of May 15, 2026, spot at $37.66, ATM IV 38.80%, IV rank 10.25%, expected move 11.12%. The strangle on ALKS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on ALKS specifically: ALKS IV at 38.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a ALKS strangle, with a market-implied 1-standard-deviation move of approximately 11.12% (roughly $4.19 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALKS expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALKS should anchor to the underlying notional of $37.66 per share and to the trader's directional view on ALKS stock.

ALKS strangle setup

The ALKS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALKS near $37.66, the first option leg uses a $40.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALKS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALKS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$40.00	$0.93
Buy 1	Put	$36.00	$1.08

ALKS strangle risk and reward

Net Premium / Debit: -$200.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$200.00
Breakeven(s): $34.00, $42.00
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ALKS strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ALKS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$3,399.00
$8.34	-77.9%	+$2,566.43
$16.66	-55.8%	+$1,733.85
$24.99	-33.7%	+$901.28
$33.31	-11.5%	+$68.71
$41.64	+10.6%	-$36.14
$49.96	+32.7%	+$796.44
$58.29	+54.8%	+$1,629.01
$66.62	+76.9%	+$2,461.58
$74.94	+99.0%	+$3,294.16

When traders use strangle on ALKS

Strangles on ALKS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALKS chain.

ALKS thesis for this strangle

The market-implied 1-standard-deviation range for ALKS extends from approximately $33.47 on the downside to $41.85 on the upside. A ALKS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ALKS IV rank near 10.25% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ALKS at 38.80%. As a Healthcare name, ALKS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALKS-specific events.

ALKS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALKS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALKS alongside the broader basket even when ALKS-specific fundamentals are unchanged. Always rebuild the position from current ALKS chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ALKS?: A strangle on ALKS is the strangle strategy applied to ALKS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ALKS stock trading near $37.66, the strikes shown on this page are snapped to the nearest listed ALKS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ALKS strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ALKS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 38.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$200.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ALKS strangle?: The breakeven for the ALKS strangle priced on this page is roughly $34.00 and $42.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALKS market-implied 1-standard-deviation expected move is approximately 11.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ALKS?: Strangles on ALKS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALKS chain.
How does current ALKS implied volatility affect this strangle?: ALKS ATM IV is at 38.80% with IV rank near 10.25%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.